Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS

K. L. Ferrante, J. Shefner, H. Zhang, Rebecca Betensky, M. O'Brien, H. Yu, M. Fantasia, J. Taft, M. F. Beal, B. Traynor, K. Newhall, P. Donofrio, J. Caress, C. Ashburn, B. Freiberg, C. O'Neill, C. Paladenech, T. Walker, A. Pestronk, B. Abrams & 5 others J. Florence, R. Renna, J. Schierbecker, B. Malkus, M. Cudkowicz

Research output: Contribution to journalArticle

Abstract

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

Original languageEnglish (US)
Pages (from-to)1834-1836
Number of pages3
JournalNeurology
Volume65
Issue number11
DOIs
StatePublished - Dec 1 2005

Fingerprint

coenzyme Q10
Electrons
Safety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., ... Cudkowicz, M. (2005). Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology, 65(11), 1834-1836. https://doi.org/10.1212/01.wnl.0000187070.35365.d7

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. / Ferrante, K. L.; Shefner, J.; Zhang, H.; Betensky, Rebecca; O'Brien, M.; Yu, H.; Fantasia, M.; Taft, J.; Beal, M. F.; Traynor, B.; Newhall, K.; Donofrio, P.; Caress, J.; Ashburn, C.; Freiberg, B.; O'Neill, C.; Paladenech, C.; Walker, T.; Pestronk, A.; Abrams, B.; Florence, J.; Renna, R.; Schierbecker, J.; Malkus, B.; Cudkowicz, M.

In: Neurology, Vol. 65, No. 11, 01.12.2005, p. 1834-1836.

Research output: Contribution to journalArticle

Ferrante, KL, Shefner, J, Zhang, H, Betensky, R, O'Brien, M, Yu, H, Fantasia, M, Taft, J, Beal, MF, Traynor, B, Newhall, K, Donofrio, P, Caress, J, Ashburn, C, Freiberg, B, O'Neill, C, Paladenech, C, Walker, T, Pestronk, A, Abrams, B, Florence, J, Renna, R, Schierbecker, J, Malkus, B & Cudkowicz, M 2005, 'Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS', Neurology, vol. 65, no. 11, pp. 1834-1836. https://doi.org/10.1212/01.wnl.0000187070.35365.d7
Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005 Dec 1;65(11):1834-1836. https://doi.org/10.1212/01.wnl.0000187070.35365.d7
Ferrante, K. L. ; Shefner, J. ; Zhang, H. ; Betensky, Rebecca ; O'Brien, M. ; Yu, H. ; Fantasia, M. ; Taft, J. ; Beal, M. F. ; Traynor, B. ; Newhall, K. ; Donofrio, P. ; Caress, J. ; Ashburn, C. ; Freiberg, B. ; O'Neill, C. ; Paladenech, C. ; Walker, T. ; Pestronk, A. ; Abrams, B. ; Florence, J. ; Renna, R. ; Schierbecker, J. ; Malkus, B. ; Cudkowicz, M. / Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. In: Neurology. 2005 ; Vol. 65, No. 11. pp. 1834-1836.
@article{1edfa3f472ad4e40ab0ae86c49f647d4,
title = "Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS",
abstract = "An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.",
author = "Ferrante, {K. L.} and J. Shefner and H. Zhang and Rebecca Betensky and M. O'Brien and H. Yu and M. Fantasia and J. Taft and Beal, {M. F.} and B. Traynor and K. Newhall and P. Donofrio and J. Caress and C. Ashburn and B. Freiberg and C. O'Neill and C. Paladenech and T. Walker and A. Pestronk and B. Abrams and J. Florence and R. Renna and J. Schierbecker and B. Malkus and M. Cudkowicz",
year = "2005",
month = "12",
day = "1",
doi = "10.1212/01.wnl.0000187070.35365.d7",
language = "English (US)",
volume = "65",
pages = "1834--1836",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS

AU - Ferrante, K. L.

AU - Shefner, J.

AU - Zhang, H.

AU - Betensky, Rebecca

AU - O'Brien, M.

AU - Yu, H.

AU - Fantasia, M.

AU - Taft, J.

AU - Beal, M. F.

AU - Traynor, B.

AU - Newhall, K.

AU - Donofrio, P.

AU - Caress, J.

AU - Ashburn, C.

AU - Freiberg, B.

AU - O'Neill, C.

AU - Paladenech, C.

AU - Walker, T.

AU - Pestronk, A.

AU - Abrams, B.

AU - Florence, J.

AU - Renna, R.

AU - Schierbecker, J.

AU - Malkus, B.

AU - Cudkowicz, M.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

AB - An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

UR - http://www.scopus.com/inward/record.url?scp=33645068499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645068499&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000187070.35365.d7

DO - 10.1212/01.wnl.0000187070.35365.d7

M3 - Article

VL - 65

SP - 1834

EP - 1836

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -